Kyverna Therapeutics (KYTX)
Develops miv-cel, an autologous CD19 CAR-T candidate for B-cell-driven autoimmune diseases.
$7.01
vs last close−0.50 (−6.72%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 61.26% | 37.89M shares | |
|---|---|---|---|
| 128 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.98% | 1.23M shares | |
| 13 holders · as of May 29, 2026 | |||
| Strategic holders | 7.53% | 4.66M shares | |
| 2 holders · as of Feb 6, 2026 | |||
| Other | ≈ 29.23% | 18.07M shares | |
| remainder | |||
61.84M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
128 holders · 37.89M shares · 33 new positions · 71 increased · 26 reduced · 23 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Gordonmd Global Investments LP | 4.24M | 6.86% | 0 | Aug 14, 2026 |
| Gilead Sciences, Inc. | 4.13M | 6.67% | 0 | Aug 3, 2026 |
| BlackRock, Inc. | 3.13M | 5.07% | +2.26M | Aug 7, 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.89M | 4.67% | −225.0K | Aug 14, 2026 |
| Aigh Capital Management LLC | 2.80M | 4.52% | +795.8K | Aug 7, 2026 |
| Deerfield Management Company, L.P. (Series C) | 2.00M | 3.23% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.90M | 3.07% | +114.1K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 1.19M | 1.92% | −369.3K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Dr. Sean E. Harper (“Harper”)incl. Westlake BioPartners Fund I, L.P. (“Westlake Fund I”), Westlake BioPartners Opportunity Fund I, L.P. (“Westlake Opportunity Fund I”) +3 more | 10.50% | 4.52M | 13G | Nov 12, 2024 |
| GordonMD Global Investments LP | 7.00% | 3.06M | 13G | Nov 17, 2025 |
| Westlake BioPartners Fund I, L.P. ("Westlake Fund I") | 6.30% | 3.79M | 13G | Feb 6, 2026 |
| JPMorgan Chase & Co. | 5.50% | 2.38M | Oct 10, 2024 | |
| Bain Capital Life Sciences Opportunities III, LP | 5.40% | 3.11M | 13G | Feb 17, 2026 |
| BlackRock, Inc. | 5.10% | 3.10M | 13G | Jul 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Dec 18, 2025 | Westlake BioPartners Opportunity Fund I, L.P.10 percent owner | Purchase | 133,333 | $7.50 | 869,317 |
| Dec 18, 2025 | Beth C. Seidenbergdirector | Purchase | 133,333 | $7.50 | 869,317 |
| Dec 15, 2025 | Karen Marie Walkerofficer: Chief Technology Officer | Sale | 23,998 | $12.20 | 22,636 |
House and Senate disclosures
Not reported.